mozavaptan has been researched along with Disease Models, Animal in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Baeßler, B; Benzing, T; Borgal, L; Dafinger, C; Franke, M; Göbel, H; Höhne, M; Koerber, F; Maintz, D; Persigehl, T; Schermer, B; Vechtel, J | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
| de Heer, E; Gansevoort, RT; Meijer, E; Peters, DJ; van Goor, H; Veraar, KA; Versteeg, IB; Zittema, D | 1 |
| Berkó, A; László, F; László, FA; Molnár, AH; Párducz, A; Rojik, I; Varga, C | 2 |
| Doi, K; Kakigi, A; Nishimura, M; Okada, T; Takeda, T | 2 |
| de Heer, E; de Jong, PE; de Krey, SR; Gansevoort, RT; Leonhard, WN; Meijer, E; Mulder, GM; Peters, DJ; Struck, J; van den Born, J; van der Wal, AM; van Goor, H | 1 |
| Devuyst, O; Serra, A; Wang, X | 1 |
| Gattone, VH; Harris, PC; Torres, VE; Wang, X | 1 |
| Gattone, VH; Harris, PC; Qian, Q; Somlo, S; Torres, VE; Wang, X | 1 |
| Aloisi, C; Buemi, M; Calapai, G; Cavallaro, E; Corica, F; Di Pasquale, G; Floccari, F; Frisina, N; Nostro, L; Ruello, A; Sturiale, A | 1 |
| Gattone, V; Harris, PC; Torres, VE; Wang, X | 1 |
| Arata, T; Ejima, Y; Hatano, R; Kazama, I; Matsubara, M; Michimata, M; Miyama, N; Sanada, S; Sasaki, S; Sato, A; Satomi, S; Suzuki, M | 1 |
| Harada, K; Hashimoto, M; Mimura, Y; Ogura, T; Oishi, T; Ota, Z; Otsuka, F; Yamauchi, T | 1 |
| Kanno, Y; Okada, H; Saruta, T; Suzuki, H | 1 |
| Arrizurieta, EE; Bertuccio, CA; Ibarra, FR; Martin, RS; Toledo, JE | 1 |
1 review(s) available for mozavaptan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
17 other study(ies) available for mozavaptan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease.
Topics: Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cysts; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Early Diagnosis; Female; Humans; Image Processing, Computer-Assisted; Kidney; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Mutation; NIMA-Related Kinases; Polycystic Kidney Diseases; Proof of Concept Study; Time Factors; Treatment Outcome; Young Adult | 2017 |
Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cysts; Disease Models, Animal; Drinking; Female; Kidney; Male; Mice, Knockout; Organ Size; Polycystic Kidney, Autosomal Dominant; Protein Kinase C; Time Factors; Water | 2016 |
Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Body Water; Brain; Brain Edema; Carotid Arteries; Disease Models, Animal; Electrolytes; Humans; Hypoxia, Brain; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Survival Rate | 2008 |
Time course changes of vasopressin-induced enlargement of the rat intrastrial space and the effects of a vasopressin type 2 antagonist.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Endolymphatic Hydrops; Injections, Subcutaneous; Meniere Disease; Microscopy, Electron, Transmission; Premedication; Rats; Stria Vascularis | 2009 |
Bumetanide-induced enlargement of the rat intrastrial space and effects of a vasopressin type 2 antagonist.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Bumetanide; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Homeostasis; Premedication; Rats; Rats, Wistar; Stria Vascularis | 2010 |
Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Kidney; Male; Mice; Mice, Knockout; Polycystic Kidney, Autosomal Dominant; Protein Kinase C | 2011 |
Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Female; Male; Polycystic Kidney, Autosomal Dominant | 2011 |
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Aquaporin 6; Aquaporins; Benzazepines; Cyclic AMP; Disease Models, Animal; Disease Progression; Humans; Kidney; Mice; Polycystic Kidney Diseases; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; TRPP Cation Channels | 2003 |
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Mice; Phenotype; Polycystic Kidney, Autosomal Dominant | 2004 |
Aquaporin-2 water channels in spontaneously hypertensive rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Aquaporins; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Hypertension; Male; Osmolar Concentration; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasopressins | 2004 |
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan | 2005 |
Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Diabetes Insipidus, Nephrogenic; Disease Models, Animal; Drug Synergism; Furosemide; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Lithium Chloride; Male; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin | 2007 |
Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Water; Brain; Brain Edema; Brain Ischemia; Disease Models, Animal; Kidney; Male; Microscopy, Electron, Transmission; Rats; Receptors, Vasopressin; Sodium; Survival Rate; Treatment Outcome; Vasopressins; Water-Electrolyte Balance | 2008 |
Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats.
Topics: Animals; Benzazepines; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Heart Rate; Male; Piperidines; Quinolones; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Vasopressin; Time Factors | 1995 |
Effects of novel, nonpeptide vasopressin antagonists on progressive nephrosclerosis in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Diuresis; Glomerulosclerosis, Focal Segmental; Hypertension; Kidney; Male; Nephrectomy; Nephrosclerosis; Piperidines; Proteinuria; Quinolones; Rats; Rats, Inbred SHR | 1995 |
Endogenous vasopressin regulates Na-K-ATPase and Na(+)-K(+)-Cl(-) cotransporter rbsc-1 in rat outer medulla.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Kidney Failure, Chronic; Kidney Medulla; Male; Mucoproteins; Rats; Rats, Wistar; Receptors, Vasopressin; Sodium-Potassium-Chloride Symporters; Sodium-Potassium-Exchanging ATPase; Solute Carrier Family 12, Member 1; Uromodulin; Vasopressins; Water-Electrolyte Balance | 2002 |